Challenges in the delivery of peptide drugs: an industry perspective

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Shive M, Anderson J. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28(1), 5–24 (1997).
  Medline CASGoogle Scholar
• 2 Hoffman AS. The origins and evolution of ‘controlled’ drug delivery systems. J. Control. Release 132(3), 153–163 (2008).
  Medline CASGoogle Scholar
• 3 Klose D, Siepmann F, Elkharraz K, Siepmann J. PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int. J. Pharm. 354(1–2), 95–103 (2007).
  MedlineGoogle Scholar
• 4 Tracy M.A, Ward K.L, Firouzabadian L, Wang Y, Dong N, Qian R, Zhang Y. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20(11), 1057–1062 (1999).
  Medline CASGoogle Scholar
• 5 Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. 364(2), 298–327 (2008).
  Medline CASGoogle Scholar
• 6 Kim HK, Chung HJ, Park TG. Biodegradable polymeric microspheres with ‘open/closed’ pores for sustained release of human growth hormone. J. Control. Release 112(2), 167–174 (2006).
  Medline CASGoogle Scholar
• 7 Lewis AL, Illum L. Formulation strategies for sustained release of proteins. Ther. Deliv. 1(3), 457–479 (2010).
  CASGoogle Scholar
• 8 Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21(23), 2475–2490 (2000).
  Medline CASGoogle Scholar
• 9 Davies OR, Lewis AL, Whitaker MJ, Tai H, Shakesheff KM, Howdle SM. Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering. Adv. Drug Deliv. Rev. 60(3), 373–387 (2008).
  Medline CASGoogle Scholar
• 10 Kranz H, Bodmeier R. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles. Eur. J. Pharm. Sci. 34(2–3), 164–172 (2008).
  Medline CASGoogle Scholar
• 11 Luan X, Bodmeier R. Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly(lactide-co-glycolide) microparticles. Eur. J. Pharm. Biopharm. 63(2), 205–214 (2006).
  Medline CASGoogle Scholar
• 12 European Commission REACH Legislation. http://ec.europa.eu/enterprise/sectors/chemicals/reach/index_en.htm.
  Google Scholar
• 13 Siepmann J, Faisant N, Akiki J, Richard J, Benoit JP. Effect of the size of biodegradable microparticles on drug release: experiment and theory. J. Control. Release 96(1), 123–134 (2004).• Importance of poly(lactic-co-glycolic)acid (PLGA) microparticle geometry on control of drug release.
  Medline CASGoogle Scholar
• 14 Klose D, Siepmann F, Elkharraz K, Krenzlin S, Siepmann J. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int. J. Pharm. 314(2), 198–206 (2006).
  Medline CASGoogle Scholar
• 15 Faisant N, Siepmann J, Richard J, Benoit J. Mathematical modeling of drug release from bioerodible microparticles: effect of gamma-irradiation. Eur. J. Pharm. Biopharm. 56(2), 271–279 (2003).
  Medline CASGoogle Scholar
• 16 Vladisavljević GT, Williams RA. Recent developments in manufacturing emulsions and particulate products using membranes. Adv. Colloid Interface Sci. 113(1), 1–20 (2005).
  Medline CASGoogle Scholar
• 17 Joanicot M, Ajdari A. Applied physics: droplet control for microfluidics. Science 309(5736), 887–888 (2005).
  Medline CASGoogle Scholar
• 18 Björnmalm M, Yan Y, Caruso F. Engineering and evaluating drug delivery particles in microfluidic devices. J. Control. Release doi:10.1016/j.jconrel.2014.04.030 (2014) (Epub ahead of print).
  MedlineGoogle Scholar
• 19 Bocanegra R, José Luis Sampedro AG-C, Marquez M. Monodisperse structured multi-vesicle microencapsulation using flow-focusing and controlled disturbance. J. Microencapsul. 22(7), 745–759 (2005).
  Medline CASGoogle Scholar
• 20 Pérez C, Castellanos IJ, Costantino HR, Al-Azzam W, Griebenow K. Recent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers. J. Pharm. Pharmacol. 54(3), 301–313 (2002).
  Medline CASGoogle Scholar
• 21 Hao J, Whitaker MJ, Wong B, Serhatkulu G, Shakesheff KM, Howdle SM. Plasticization and spraying of poly (DL-lactic acid) using supercritical carbon dioxide: control of particle size. J. Pharm. Sci. 93(4), 1083–1090 (2004).
  Medline CASGoogle Scholar
• 22 Whitaker MJ, Hao J, Davies OR et al. The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. J. Control Release 101(1–3), 85–92 (2005).
  Medline CASGoogle Scholar
• 23 Jordan F, Naylor A, Kelly CA, Howdle SM, Lewis A, Illum L. Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: in vivo studies. J. Control. Release 141(2), 153–160 (2010).
  Medline CASGoogle Scholar
• 24 Pini R, Storti G, Mazzotti M, Tai H, Shakesheff KM, Howdle SM. Sorption and swelling of poly (DL -lactic acid) and poly (lactic-co-glycolic acid) in supercritical CO₂. Macromol. Symp. 259(1), 197–202 (2007).
  CASGoogle Scholar
• 25 Chen Yulin, Ping Ma, Shuangying Gui. Cubic and hexagonal liquid crystals as drug delivery systems. Biomed Res. Int. doi: 10.1155/2014/815981 (2014) (Epub ahead of print).
  Google Scholar
• 26 Norling Tomas, Lading Pia, Engström Sven, Larsson Kåre, Niels Krog SSN. Formulation of a drug delivery system based on a mixture of monoglycerides and triglycerides for use in the treatment of periodontal disease. J. Clin. Periodontol. 19(9), 687–692 (1992).
  Medline CASGoogle Scholar
• 27 Ruiz-Hornillos J, Henríquez-Santana A, Moreno-Fernández A, González IG, Sánchez SR. Systemic allergic dermatitis caused by the solvent of Eligard. Contact Dermatitis 61(6), 355–356 (2009).
  Medline CASGoogle Scholar
• 28 Asmus LR, Tille J-C, Kaufmann B et al. In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer. J. Control. Release 165(3), 199–206 (2013).
  Medline CASGoogle Scholar
• 29 Heller J, Barr J. Poly(ortho esters): from concept to reality. Biomacromolecules 5(5), 1625–1632 (2004).
  Medline CASGoogle Scholar
• 30 Einmahl S, Capancioni S, Schwach-Abdellaoui K, Moeller M, Behar-Cohen F, Gurny R. Therapeutic applications of viscous and injectable poly(ortho esters). Adv. Drug Deliv. Rev. 53(1), 45–73 (2001).
  Medline CASGoogle Scholar
• 31 Heller J, Barr J, Ng SY, Abdellauoi KS, Gurny R. Poly(ortho esters): synthesis, characterization, properties and uses. Adv. Drug Deliv. Rev. 54(7), 1015–1039 (2002).
  Medline CASGoogle Scholar
• 32 Heller J, Barr J, Ng SY et al. Poly(ortho esters): their development and some recent applications. Eur. J. Pharm. Biopharm. 50(1), 121–128 (2000).
  Medline CASGoogle Scholar
• 33 Einmahl S, Zignani M, Varesio E et al. Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester). Int. J. Pharm. 185(2), 189–198 (1999).
  Medline CASGoogle Scholar
• 34 Chan Y-P, Meyrueix R, Kravtzoff R, Nicolas F, Lundstrom K. Review on Medusa^®: a polymer-based sustained release technology for protein and peptide drugs. Expert Opin. Drug Deliv. 4(4), 441–451 (2007).
  Medline CASGoogle Scholar
• 35 Valéry C, Paternostre M, Robert B et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc. Natl. Acad. Sci. USA 100(18), 10258–10262 (2003).
  Medline CASGoogle Scholar
• 36 Valéry C, Artzner F, Robert B et al. Self-association process of a peptide in solution: from beta-sheet filaments to large embedded nanotubes. Biophys. J. 86(4), 2484–2501 (2004).• Investigations into the mechanism of peptide self-assembly into nanotubes useful for injectable sustained release.
  Medline CASGoogle Scholar
• 37 Valéry C, Pouget E, Pandit A et al. Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach. Biophys. J. 94(5), 1782–1795 (2008).
  Medline CASGoogle Scholar
• 38 Pouget E, Fay N, Dujardin E et al. Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates. J. Am. Chem. Soc. 132(12), 4230–4241 (2010).
  Medline CASGoogle Scholar
• 39 Van Grondelle W, Iglesias CL, Coll E et al. Spontaneous fibrillation of the native neuropeptide hormone Somatostatin-14. J. Struct. Biol. 160(2), 211–223 (2007).
  Medline CASGoogle Scholar
• 40 Maji SK, Schubert D, Rivier C, Lee S, Rivier JE, Riek R. Amyloid as a depot for the formulation of long-acting drugs. PLoS Biol. 6(2), e17 (2008).
  MedlineGoogle Scholar
• 41 Reynolds Lucy, McKee M. Serve the people or close the sale? Profit-driven overuse of injections and infusions in China's market-based healthcare system. Int. J. Health Plann. Manage. 26(4), 449–470 (2011).
  MedlineGoogle Scholar
• 42 Fransén N, Bredenberg S, Björk E. Clinical study shows improved absorption of desmopressin with novel formulation. Pharm. Res. 26(7), 1618–1625 (2009).• Comparison of pharmacokinetics and patient acceptability of nasal and oral peptide formulations.
  Medline CASGoogle Scholar
• 43 Brayden DJ, Maher S. Oral absorption enhancement: taking the next steps in therapeutic delivery. Ther. Deliv. 1(1), 5–9 (2010).
  CASGoogle Scholar
• 44 Welling SH, Hubálek F, Jacobsen J, Brayden DJ, Rahbek UL, Buckley ST. The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur. J. Pharm. Biopharm. 86(3), 544–551 (2014).
  Medline CASGoogle Scholar
• 45 Rosenmayr-Templeton L. The oral delivery of peptides and proteins: established versus recently patented approaches. Pharm. Pat. Anal. 2(1), 125–145 (2013).
  CASGoogle Scholar
• 46 Binkley N, Bolognese M, Sidorowicz-Bialynicka A et al. A Phase III trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J. Bone Miner. Res. 27(8), 1821–1829 (2012).•• Clinicially demonstrated increased efficacy of the oral peptide compared with the marketed nasal spray.
  Medline CASGoogle Scholar
• 47 Mehta N. Clinical development of an oral formulation of recombinant salmon calcitonin At: The Peptide Conference 2010. Cambridge, UK 30–31 March, 2010.
  Google Scholar
• 48 Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen CKM. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH(2)] in postmenopausal women with osteoporosis. Bone 53(1), 160–166 (2013).
  Medline CASGoogle Scholar
• 49 Tuvia S, Atsmon J, Teichman SL et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab. 97(7), 2362–2369 (2012).
  Medline CASGoogle Scholar
• 50 Tuvia S, Salama P, Weinstein I et al. OR14,80 Octreolin^TM, a safe oral alternative for parenteral octreotide treatment. Growth Horm. IGF Res. 20(Suppl.1), S35–S36 (2010).
  Google Scholar
• 51 Merrion Pharmacueticals. www.merrionpharma.com/content/investors/archive/2014/290514.asp.
  Google Scholar
• 52 Business Standard. Biocon's oral insulin project expected to be delayed further. www.business-standard.com/article/companies/biocon-s-oral-insulin-project-expected-to-be-delayed-further-113122300378_1.html.
  Google Scholar
• 53 Eldor R, Arbit E, Corcos A, Kidron M. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS ONE 8(4), e59524 (2013).
  Medline CASGoogle Scholar
• 54 Related T, Events A. The GTC Diabetes Summit. Oramed pharmaceuticals presents data from Phase IIA trial with ORMD-0801 in Type 2 diabetes. At: the 2014 Diabetes Summit. 2014, Cambridge Massachusetts, USA April 24, 2014.
  Google Scholar
• 55 Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahrén B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19(8), 843–848 (1996).
  Medline CASGoogle Scholar
• 56 Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B. GLP-1 tablet in Type 2 diabetes in fasting and postprandial conditions. Diabetes Care 20(12), 1874–1879 (1997).
  Medline CASGoogle Scholar
• 57 Damme Van, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 14(27), 454–459 (2009).
  Google Scholar
• 58 Hafner R, Couroux P, Armstrong K, Patel D, Larche M, Haumann B. Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes. Clin. Transl. Allergy 3(Suppl. 2), doi:10.1186/2045-7022-3-S2-O7 (2013).
  Google Scholar
• 59 Radius Pharmaceuticals. Radius announces topline data from Phase II of BA058. http://radiuspharm.mwnewsroom.com/press-releases/radius-announces-positive-topline-data-from-phase–1080683.
  Google Scholar
• 60 Zosano Pharmaceuticals. Zosano pharma, Inc., announces completes positive end-of-phase 2 meeting with FDA regarding zp- pth patch for osteoporosis. www.zosanopharma.com/index.php/Press-Release-12–19–2008.html.
  Google Scholar
• 61 Daddona PE, Matriano JA, Mandema J, Maa YF. Parathyroid hormone (1–34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm. Res. 28(1), 159–165 (2011).•• Demonstrated increased efficacy in man through switching from injectable parathyroid hormone (PTH) to transdermal PTH.
  Medline CASGoogle Scholar
• 62 Maggio ET. Intravail TM: highly effective intranasal delivery of peptide and protein drugs. Expert Opin. Drug Deliv. 3(4), 529–539 (2006).
  Medline CASGoogle Scholar
• 63 Eddy P, Krause D, Merutka G, Macdonald B. Intranasal (IN) pharmacokinetics (PK) and bioavailability of ZT-031: a novel parathyroid hormone (PTH) analog. Presented at: ASBMR 30 Annual Meeting, 16 September 2009.
  Google Scholar
• 64 Lewis AL, Jordan F, Illum L. CriticalSorb^TM: enabling systemic delivery of macromolecules via the nasal route. Drug Deliv. Transl. Res. 3(1), 26–32 (2012).
  Google Scholar
• 65 Illum L. Nasal drug delivery: recent developments and future prospects. J. Control. Release 161(2), 254–263 (2012).
  Medline CASGoogle Scholar
• 66 Bzik V, Lewis A, Illum L, Brayden DJ. CriticalSorb promotes permeation of flux markers across rat colonic mucosae. Pharm. Res. 29(9), 2543–2554 (2012).
  MedlineGoogle Scholar
• 67 Critical Pharmaceuticals. Critical pharmaceuticals start dosing in Phase I on nasal PTH. www.criticalpharmaceuticals.com/latest/news/cp046-start-clinical.
  Google Scholar
• 68 Hrkach J, Von Hoff D, Mukkaram Ali M et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128–139 (2012).
  Google Scholar
• 69 Gaillard PJ, Appeldoorn CCM, Dorland R et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3–101). PLoS ONE 9(1), e82331 (2014).
  MedlineGoogle Scholar